Replimune Group, Inc. (REPL)
Last updated: 2026-10-21 08:33:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Replimune Group, Inc. (REPL) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $10.92, with a market capitalization of $1.04B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.50 to $16.33. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.04B | |
$11.53 | |
$54.85 | |
$1.50 | |
$11.42 | |
23.06K | |
4.02M | |
-- | |
$16.33 | |
$1.50 | |
-- | |
-- |
Replimune Group, Inc. (REPL) Pre-Market Stock Price
Replimune Group, Inc. (REPL) is trading at $10.92 in pre-market trading as of 2026-10-21 08:22:00, down 4.37% ($0.50) from the previous close of $11.42
Pre-market trading shows how investors are pricing REPL before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Replimune Group, Inc. (REPL) 7-Day Stock Price Change
Over the past seven days, Replimune Group, Inc. (REPL) moved from $13.07 to $10.92, representing a decline of 16.44% ($2.15).
The stock traded between $10.67 and $13.56 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.56 million shares, down versus the previous seven-day period, indicating lower trading activity.
REPL 52-Week Price Position
Position in Range: 63.5%
REPL is currently trading at $10.92, placing it 63.5% of the way from its 52-week low of $1.50 to its 52-week high of $16.33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Replimune Group, Inc. (REPL)?
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Replimune Group, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 465 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Replimune Group, Inc. (REPL) Stock on MEXC
Eligible investors can buy real shares of Replimune Group, Inc. (REPL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Replimune Group, Inc. (REPL) stock price today?
2.Is REPL stock going up or down today?
3.What is REPL pre-market price?
4.What is REPL after-hours price?
5.Is REPL stock trading now?
6.Where does REPL sit relative to its 52-week high and low?
7.What sector is Replimune Group, Inc. in?
8.What is Replimune Group, Inc.'s market capitalization and where is it listed?
9.How is REPL valued in terms of P/E ratio and EPS?
10.Does Replimune Group, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
REPL Stock Calculator
Estimate the value between REPL shares and USD.
REPL Shares to USD
1.00 REPL shares = 10.921 USD
Calculations are estimates based on the latest available price and are for reference only.


